TRANSGENOMIC SELLS ION CHROMATOGRAPHY PRODUCT LINE AND ASSETS TO EDGE BIOSYSTEMS, INC. -$2.1 Million Sale Continues Transgenomic's Strategy of Selectively Monetizing Legacy Assets and Generating Non-Dilutive Cash to Allo

TRANSGENOMIC SELLS ION CHROMATOGRAPHY

PRODUCT LINE AND ASSETS TO EDGE

-$2.1 Million Sale Continues Transgenomic's

Strategy of Selectively Monetizing Legacy Assets and

Generating Non-Dilutive Cash to Allow Focus

on Products for High Growth Molecular Diagnostics

and Personalized Medicine Sectors-

OMAHA, Neb. (September 9, 2015) - Transgenomic, Inc.

(NASDAQ: TBIO) today announced that it has sold its ion chromatography (IC) product line and related assets to Edge BioSystems,

Inc. (EdgeBio), a portfolio company of the investment firm StoneCalibre. EdgeBio is a specialized manufacturer and distributor

of DNA sequencing sample preparation and clean-up products.

Under the terms of the agreement, Transgenomic transferred rights

to its ion chromatography products, licenses, technology, know-how and trademarks to EdgeBio, along with product inventory, for

approximately $2.1 million in cash. Further terms of the agreement were not disclosed.

Ion chromatography is a chemical analysis technique that separates

and analyzes different substances according to their affinities for chemically stable, highly reactive synthetic ion exchangers.

The IC product line includes a wide range of specialty ion chromatography columns that are designed to run on a variety of chromatograph

Paul Kinnon, President and Chief Executive Officer of Transgenomic,

commented, "An important part of our revitalization strategy is to selectively monetize non-core legacy businesses and product

lines so that we can focus our resources on commercialization of Multiplexed ICE COLD-PCRTM (MX-ICP) for high value,

high growth clinical applications, such as liquid biopsies for targeted cancer therapy and patient monitoring. This asset monetization

strategy frees up cash to help advance our commercialization efforts for MX-ICP. Transgenomic will continue to pursue opportunities

to optimize our asset deployment and product mix, and we expect to complete additional asset monetizations in the coming months."

About Edge BioSystems

Established in 1990, Edge Biosystems is

headquartered in Gaithersburg, Maryland. EdgeBio's consumable products are critical components in the DNA sequencing process,

allowing researchers to determine the exact genetic make-up of DNA for use in clinical and diagnostic labs, food testing, microbial

identification, forensic identification, molecular medicine, ancestry studies and other applications. EdgeBio has built a solid

reputation as a sequencing purification supplier of choice stemming from its consistent, high-quality product performance backed

by its proprietary formulations. EdgeBio was acquired by StoneCalibre in 2014. For more information, visit www.edgebio.com.

Headquartered in Century City, CA, StoneCalibre

is a privately funded investment firm specializing in the acquisition of lower middle market companies. Founded by Brian Wall

in 2012, StoneCalibre is focused on making investments in both special situations and quality long-term capital investment opportunities.

For more information please visit our website at www.stonecalibre.com.

Transgenomic, Inc. is a global biotechnology

company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic technologies,

such as its revolutionary ICE COLD-PCR and its unique genetic tests provided through its Patient Testing business. The company

also provides specialized clinical and research services to biopharmaceutical companies developing targeted therapies and sells

equipment, reagents and other consumables for applications in molecular testing and cytogenetics. Transgenomic's diagnostic

technologies are designed to improve medical diagnoses and patient outcomes.

Forward-Looking Statements

statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the

Private Securities Litigation Reform Act of 1995, which involve known and unknown risks,

uncertainties and other factors that may cause actual results to be materially different from any future results, performance

or achievements expressed or implied by such statements. These forward-looking statements include statements relating to Transgenomic's

revitalization and asset monetization strategy, the potential applications for Multiplexed ICE COLD-PCRTM, the availability

of cash for commercialization efforts and the expected timing for its asset monetization strategy. The known risks, uncertainties

and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the

Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and

performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of

the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect

to all statements contained in this press release. All information in this press release is as of the date of the release and

Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required